Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400123.RAf5XY7H3Vr1gaSNgv19f8y10r1ppb-lC-7srP5S5FsEg130_provenance.
• NP1400120.RANy8wH4I930R5LO_g3O2OCutjRiYONl0GmzK0-38GtDU130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400120.RANy8wH4I930R5LO_g3O2OCutjRiYONl0GmzK0-38GtDU130_provenance.
• NP1400121.RA_mcnwVphdN3ZwT86JJuqQjcAzIZarPBS_TQONA2adXY130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400121.RA_mcnwVphdN3ZwT86JJuqQjcAzIZarPBS_TQONA2adXY130_provenance.
• NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400122.RAwphvN4P5ThI-OsW6d1FrxA30Vu-wUe5E_Olq8X_IbJM130_provenance.
• NP1400124.RAwy7XMPoC_JIiagxm1H8QyXUy-KhKHiXypaUO-Byr0gs130_assertion description "[Specific balanced chromosome aberrations in t-MDS and t-AML involving chromosome bands 11q23 and 21q22, inv(16), t(15;17), and t(9;22) are all significantly associated with previous therapy with DNA topoisomerase II inhibitors, as compared to the uncharacteristic balanced aberrations most commonly observed after therapy with alkylating agents.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1400124.RAwy7XMPoC_JIiagxm1H8QyXUy-KhKHiXypaUO-Byr0gs130_provenance.